Company intelligence / Profile preview

OpenBiome

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Commercial

Overview

OpenBiome has provided investigational fecal microbiota transplantation to over 65,000 patients with recurrent C. difficile infections and supported more than 40 clinical studies across a range of disease areas. The organization continues to develop new live biotherapeutic therapies targeting malnutrition and supports global research into the human microbiome’s role in health and disease.

Therapeutic areas: Metabolic DisordersImmunologyNeurologyInfectious Diseases
Modalities: Live biotherapeutics (fecal microbiota transplantation / FMT)
Industry: Biotech

Drug pipeline

8 assets

biologically active human fecal material

7 more assets in the full pipeline.

Request access →

Partnerships

Collaborations with leading academic researchers globallyPartnerships with clinicians at hospitals treating rCDI

Beyond the preview

Go deeper on OpenBiome.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OpenBiome.

Explore the full profile